# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest ...
The company announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progre...
The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their co...
HC Wainwright & Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:EYEN) with a Buy and maintains $12 price target.
Eyenovia (NASDAQ:EYEN) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by...